{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:24:11Z","timestamp":1791336251815,"version":"4.3.1"},"reference-count":51,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,11,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We used the thrombin generation assay to evaluate the hypercoagulable state according to JAK2V617F mutational status in essential thrombocythemia (ET) and polycythemia vera (PV) patients. Thrombin generation was determined in the presence and absence of activated protein C (APC), and APC resistance was expressed as normalized APC sensitivity ratio (nAPCsr). Tissue factor pathway inhibitor (TFPI), total and free protein S (PS), prothrombin (FII), factor V (FV), and neutrophil elastase were measured in plasma; CD11b was measured on neutrophils. Compared with normal controls, patients had a lower endogenous thrombin potential in the absence of APC but had a higher endogenous thrombin potential in the presence of APC, showing the occurrence of APC resistance. The nAPCsr increased in JAK2V617F carriers compared with noncarriers and was highest in JAK2V617F homozygous patients. FII, FV, free PS, and TFPI levels were reduced in patients, mainly in JAK2V617F carriers. Multiple regression analysis indicated the low free PS level as major determinant of the increased nAPCsr. Elastase was increased in patients and inversely correlated with free PS. In conclusion, these data indicate the occurrence of acquired APC resistance in ET and PV patients, probably because of a reduction in free PS levels. The APC-resistant phenotype is influenced by the JAK2V617F mutational load.<\/jats:p>","DOI":"10.1182\/blood-2008-06-164087","type":"journal-article","created":{"date-parts":[[2008,9,3]],"date-time":"2008-09-03T20:53:44Z","timestamp":1220475224000},"page":"4061-4068","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":129,"title":["Thrombin generation and activated protein C resistance in patients with essential thrombocythemia and polycythemia vera"],"prefix":"10.1182","volume":"112","author":[{"given":"Marina","family":"Marchetti","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands;"},{"name":"Thrombosis and Hemostasis Center, Department of Hematology-Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Castoldi","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri M. H.","family":"Spronk","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"van Oerle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Balducci","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Center, Department of Hematology-Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiziano","family":"Barbui","sequence":"additional","affiliation":[{"name":"Research Foundation, Ospedali Riuniti di Bergamo, Bergamo, Italy; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rosing","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"ten Cate","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Laboratory for Clinical Thrombosis and Haemostasis, Cardiovascular Research Institute Maastricht, Maastricht University, Maastricht, The Netherlands;"},{"name":"Department of Internal Medicine, Division of Haematology, University Hospital Maastricht, Maastricht, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Falanga","sequence":"additional","affiliation":[{"name":"Thrombosis and Hemostasis Center, Department of Hematology-Oncology, Ospedali Riuniti di Bergamo, Bergamo, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111712571503900_B1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1182\/asheducation-2003.1.200","article-title":"Chronic myeloproliferative disorders.","author":"Spivak","year":"2003","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"2019111712571503900_B2","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.beha.2005.07.011","article-title":"Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.","volume":"19","author":"Landolfi","year":"2006","journal-title":"Best Pract Res Clin Haematol"},{"key":"2019111712571503900_B3","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1365-2141.2004.05277.x","article-title":"Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia.","volume":"128","author":"Elliott","year":"2005","journal-title":"Br J Haematol"},{"key":"2019111712571503900_B4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1055\/s-2007-976165","article-title":"Thrombosis in myeloproliferative disorders: prevalence, prognostic factors, and the role of leukocytes and JAK2V617F.","volume":"33","author":"Tefferi","year":"2007","journal-title":"Semin Thromb Hemost"},{"key":"2019111712571503900_B5","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1182\/blood-2006-09-046342","article-title":"Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.","volume":"109","author":"Carobbio","year":"2007","journal-title":"Blood"},{"key":"2019111712571503900_B6","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1182\/blood-2006-08-042515","article-title":"Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera.","volume":"109","author":"Landolfi","year":"2007","journal-title":"Blood"},{"key":"2019111712571503900_B7","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1200\/JCO.2007.15.3569","article-title":"Leukocytosis and risk stratification assessment in essential thrombocythemia.","volume":"26","author":"Carobbio","year":"2008","journal-title":"J Clin Oncol"},{"key":"2019111712571503900_B8","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111712571503900_B9","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2019111712571503900_B10","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111712571503900_B11","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2005.05858.x","article-title":"The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia.","volume":"132","author":"Cheung","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111712571503900_B12","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"2019111712571503900_B13","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1038\/sj.leu.2404854","article-title":"Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden.","volume":"21","author":"Vannucchi","year":"2007","journal-title":"Leukemia"},{"key":"2019111712571503900_B14","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","article-title":"Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.","volume":"92","author":"Finazzi","year":"2007","journal-title":"Haematologica"},{"key":"2019111712571503900_B15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1053\/j.seminhematol.2005.05.023","article-title":"Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils.","volume":"42","author":"Falanga","year":"2005","journal-title":"Semin Hematol"},{"key":"2019111712571503900_B16","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1159\/000063063","article-title":"Increased CD11\/CD18 expression and altered metabolic activity on polymorphonuclear leukocytes from patients with polycythemia vera and essential thrombocythemia.","volume":"108","author":"Burgaleta","year":"2002","journal-title":"Acta Haematol"},{"key":"2019111712571503900_B17","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1182\/blood.V96.13.4261","article-title":"Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera.","volume":"96","author":"Falanga","year":"2000","journal-title":"Blood"},{"key":"2019111712571503900_B18","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.exphem.2005.01.015","article-title":"Leukocyte-platelet interaction in patients with essential thrombocythemia and polycythemia vera.","volume":"33","author":"Falanga","year":"2005","journal-title":"Exp Hematol"},{"key":"2019111712571503900_B19","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1111\/j.1538-7836.2007.02626.x","article-title":"Platelet and coagulation activation markers in myeloproliferative diseases: relationships with JAK2 V6I7 F status, clonality, and antiphospholipid antibodies.","volume":"5","author":"Robertson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2019111712571503900_B20","doi-asserted-by":"crossref","first-page":"281","DOI":"10.3109\/00365519309088420","article-title":"Protein S degradation in vitro by neutrophil elastase.","volume":"53","author":"Eckle","year":"1993","journal-title":"Scand J Clin Lab Invest"},{"key":"2019111712571503900_B21","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1515\/bchm3.1991.372.2.1007","article-title":"Protein C degradation in vitro by neutrophil elastase.","volume":"372","author":"Eckle","year":"1991","journal-title":"Biol Chem Hoppe Seyler"},{"key":"2019111712571503900_B22","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1182\/blood.V79.7.1712.1712","article-title":"The effect of leukocyte elastase on tissue factor pathway inhibitor.","volume":"79","author":"Higuchi","year":"1992","journal-title":"Blood"},{"key":"2019111712571503900_B23","first-page":"336","article-title":"Interactions of neutrophils and coagulation proteins.","volume":"34","author":"Gillis","year":"1997","journal-title":"Semin Hematol"},{"key":"2019111712571503900_B24","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A cell-based model of hemostasis.","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"2019111712571503900_B25","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status.","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"},{"key":"2019111712571503900_B26","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.exphem.2007.01.053","article-title":"V617F JAK-2 mutation in patients with essential thrombocythemia: relation to platelet, granulocyte, and plasma hemostatic and inflammatory molecules.","volume":"35","author":"Falanga","year":"2007","journal-title":"Exp Hematol"},{"key":"2019111712571503900_B27","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1160\/TH06-07-0408","article-title":"Thrombin generation, a function test of the haemostatic-thrombotic system.","volume":"96","author":"Hemker","year":"2006","journal-title":"Thromb Haemost"},{"key":"2019111712571503900_B28","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1159\/000073575","article-title":"The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability.","volume":"32","author":"Hemker","year":"2002","journal-title":"Pathophysiol Haemost Thromb"},{"key":"2019111712571503900_B29","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1111\/j.1538-7836.2005.01430.x","article-title":"Determinants of the APTT- and ETP-based APC sensitivity tests.","volume":"3","author":"de Visser","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2019111712571503900_B30","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1365-2141.1999.01302.x","article-title":"Acquired APC resistance and oral contraceptives: differences between two functional tests.","volume":"105","author":"Curvers","year":"1999","journal-title":"Br J Haematol"},{"key":"2019111712571503900_B31","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1160\/TH07-07-0439","article-title":"Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography.","volume":"98","author":"Tchaikovski","year":"2007","journal-title":"Thromb Haemost"},{"key":"2019111712571503900_B32","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1538-7836.2007.02824.x","article-title":"Coagulation factors and the protein C system as determinants of thrombin generation in a normal population.","volume":"6","author":"Dielis","year":"2008","journal-title":"J Thromb Haemost"},{"key":"2019111712571503900_B33","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"2019111712571503900_B34","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1160\/TH05-08-0582","article-title":"Protein S levels modulate the activated protein C resistance phenotype induced by elevated prothrombin levels.","volume":"95","author":"Brugge","year":"2006","journal-title":"Thromb Haemost"},{"key":"2019111712571503900_B35","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1160\/TH04-11-0762","article-title":"Effect of oral contraceptives on the anticoagulant activity of protein S in plasma.","volume":"93","author":"Koenen","year":"2005","journal-title":"Thromb Haemost"},{"key":"2019111712571503900_B36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/ajh.10153","article-title":"Factor V Leiden mutation carriership and venous thromboembolism in polycythemia vera and essential thrombocythemia.","volume":"71","author":"Ruggeri","year":"2002","journal-title":"Am J Hematol"},{"key":"2019111712571503900_B37","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/ajh.10254","article-title":"Thrombophilic genotypes, natural anticoagulants, and plasma homocysteine in myeloproliferative disorders: relationship with splanchnic vein thrombosis and arterial disease.","volume":"72","author":"Amitrano","year":"2003","journal-title":"Am J Hematol"},{"key":"2019111712571503900_B38","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.thromres.2003.11.012","article-title":"Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations.","volume":"112","author":"Kornblihtt","year":"2003","journal-title":"Thromb Res"},{"key":"2019111712571503900_B39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/(SICI)1096-8652(199605)52:1<14::AID-AJH3>3.0.CO;2-9","article-title":"Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis.","volume":"52","author":"Bucalossi","year":"1996","journal-title":"Am J Hematol"},{"key":"2019111712571503900_B40","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1046\/j.1365-2141.2003.03987.x","article-title":"Acquired resistance to activated protein C in breast cancer patients.","volume":"120","author":"Nijziel","year":"2003","journal-title":"Br J Haematol"},{"key":"2019111712571503900_B41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2141.2006.06208.x","article-title":"Acquired resistance to activated protein C (aAPCR) in multiple myeloma is a transitory abnormality associated with an increased risk of venous thromboembolism.","volume":"134","author":"Elice","year":"2006","journal-title":"Br J Haematol"},{"key":"2019111712571503900_B42","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00001721-200204000-00003","article-title":"Activated protein C resistance in the absence of factor V Leiden mutation is a common finding in multiple myeloma and is associated with an increased risk of thrombotic complications.","volume":"13","author":"Zangari","year":"2002","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2019111712571503900_B43","doi-asserted-by":"crossref","first-page":"3676","DOI":"10.1182\/blood-2005-09-3826","article-title":"Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders.","volume":"107","author":"Passamonti","year":"2006","journal-title":"Blood"},{"key":"2019111712571503900_B44","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/ajh.2830490404","article-title":"Low proteins C and S and activation of fibrinolysis in treated essential thrombocythemia.","volume":"49","author":"Wieczorek","year":"1995","journal-title":"Am J Hematol"},{"key":"2019111712571503900_B45","doi-asserted-by":"crossref","first-page":"11896","DOI":"10.1021\/bi980520v","article-title":"Proteolysis of factor V by cathepsin G and elastase indicates that cleavage at Arg1545 optimizes cofactor function by facilitating factor Xa binding.","volume":"37","author":"Camire","year":"1998","journal-title":"Biochemistry"},{"key":"2019111712571503900_B46","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1074\/jbc.270.3.1408","article-title":"Human coagulation factor V is activated to the functional cofactor by elastase and cathepsin G expressed at the monocyte surface.","volume":"270","author":"Allen","year":"1995","journal-title":"J Biol Chem"},{"key":"2019111712571503900_B47","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1172\/JCI112822","article-title":"Cleavage of protein S by a platelet membrane protease.","volume":"79","author":"Mitchell","year":"1987","journal-title":"J Clin Invest"},{"key":"2019111712571503900_B48","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1097\/00001721-199110000-00003","article-title":"The binding and regulation of protein S by neutrophils.","volume":"2","author":"Oates","year":"1991","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2019111712571503900_B49","first-page":"159","article-title":"Phenotypic APC resistance as a marker of hypercoagulability in primitive cerebral lymphoma.","volume":"27","author":"De Lucia","year":"2005","journal-title":"Exp Oncol"},{"key":"2019111712571503900_B50","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1111\/j.1538-7836.2005.01168.x","article-title":"Mechanisms for acquired activated protein C resistance in cancer patients.","volume":"3","author":"Sarig","year":"2005","journal-title":"J Thromb Haemost"},{"key":"2019111712571503900_B51","first-page":"112","article-title":"Activated-protein-C resistance in cancer patients.","volume":"27","author":"Green","year":"1997","journal-title":"Haemostasis"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/10\/4061\/1481860\/zh802208004061.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/10\/4061\/1481860\/zh802208004061.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T12:57:34Z","timestamp":1573995454000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/10\/4061\/24578\/Thrombin-generation-and-activated-protein-C"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,15]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-06-164087","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,11,15]]}}}